Histological conversion from adenocarcinoma to small cell carcinoma of the lung after treatment with an immune checkpoint inhibitor: A case report

Naoko Miura, Taichi Matsubara, Shinkichi Takamori, Naoki Haratake, Ryo Toyozawa, Masafumi Yamaguchi, Takashi Seto, Kenichi Taguchi, Mitsuhiro Takenoyama

Research output: Contribution to journalArticlepeer-review

Abstract

The transformation of adenocarcinoma to small cell lung cancer has been reported as acquisition of resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. We here report a patient who presented histologically confirmed transformation of adenocarcinoma to small cell lung cancer after treatment with immune checkpoint inhibitor. A 65-year-old man was treated with pembrolizumab as first-line therapy and achieved temporarily a stable disease with progression after six cycles of this agent. At that stage, a transbronchial biopsy showed small cell lung cancer, and he was found to have high serum concentrations of neuron-specific enolase despite concentrations of numerous tumor markers, including neuron-specific enolase, having been within normal limits at the time of presentation. The patient thereafter was treated as a small cell carcinoma patient using cisplatin plus irinotecan and amrubicin.

Original languageEnglish
Article numberomaa026
JournalOxford Medical Case Reports
Volume2020
Issue number4-5
DOIs
Publication statusPublished - May 23 2020
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Parasitology
  • Microbiology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Histological conversion from adenocarcinoma to small cell carcinoma of the lung after treatment with an immune checkpoint inhibitor: A case report'. Together they form a unique fingerprint.

Cite this